16 March 2018 - - Doylestown, Pennsylvania-based clinical-stage biopharmaceutical company ImmunoRestoration, Inc. has signed an exclusive license agreement with the University of Pennsylvania that provides for ImmunoRestoration to commercialize certain intellectual property and technology related to the potential treatment of breast and other cancers,.
The core technology covered by the license is a novel, integrated dendritic cell-based immunization system to overcome some of the known obstacles facing anti-cancer vaccines: Immune Conditioning via Activated Innate (autologous) Transfer - ICAIT.
The platform is the result of on-going research that began more than a decade ago at the University of Pennsylvania and is led by Drs. Brian Czerniecki and Gary Koski. The company is working closely with both investigators as the research heads into its next phase.
ImmunoRestoration is developing a novel immunotherapeutic cancer vaccine platform for the targeted treatment of multiple types of cancer.
The company's primary goal is to bring its platform to market for the benefit of patients thereby creating of shareholder value.